NASDAQ:EDSA Edesa Biotech Q4 2025 Earnings Report $4.07 -0.04 (-0.97%) Closing price 09/22/2026 04:00 PM EasternExtended Trading$4.15 +0.08 (+1.94%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Edesa Biotech EPS ResultsActual EPS$0.53Consensus EPS -$0.27Beat/MissBeat by +$0.80One Year Ago EPSN/AEdesa Biotech Revenue ResultsActual Revenue$0.25 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEdesa Biotech Announcement DetailsQuarterQ4 2025Date12/12/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsEdesa Biotech's next earnings date is estimated for Friday, December 11, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Edesa Biotech Earnings HeadlinesEdesa Biotech (NASDAQ:EDSA) Rating Increased to Sell at Wall Street ZenSeptember 19, 2026 | americanbankingnews.comEDSA: Recruitment in Phase 2 Vitiligo Study Set to Get UnderwayAugust 24, 2026 | finance.yahoo.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Edesa Biotech Launches Public Offering of Common Shares, WarrantsAugust 20, 2026 | finance.yahoo.comEdesa Biotech prices $25M equity offeringAugust 20, 2026 | seekingalpha.comEdesa Biotech Announces Pricing of $25.0 Million Public OfferingAugust 19, 2026 | financialpost.comFSee More Edesa Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Edesa Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edesa Biotech and other key companies, straight to your email. Email Address About Edesa BiotechEdesa Biotech (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immune-related diseases. The company’s research programs are centered on biologic and anti-inflammatory treatments intended to address conditions for which existing treatment options may be limited. Edesa’s lead development program has included EB01, a topical, non-steroidal therapy being investigated for chronic allergic contact dermatitis, a persistent inflammatory skin condition. The company has also pursued EB05, an antibody-based treatment candidate for inflammatory complications associated with acute respiratory distress, including programs evaluated in connection with COVID-19. Founded in Canada, Edesa has conducted its development activities through clinical research and regulatory programs in North America and other international jurisdictions. The company is led by Dr. Par Nijhawan, who serves as chief executive officer and has been involved in the company’s biopharmaceutical development strategy.View Edesa Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Meta’s Muse Highlights Arm’s Growing Role in AI InfrastructureNucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportDespite Record Sales, Texas Roadhouse Has Beef With Beef CostsEncore Capital Group Has Doubled—But Its Best Tailwind Won’t Last ForeverCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One Upcoming Earnings Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
